Skip to main content
EKSO BIONICS HOLDINGS, INC. logo

EKSO BIONICS HOLDINGS, INC. — Investor Relations & Filings

Ticker · EKSO ISIN · US2826444000 LEI · 549300KPH77IVQVN2I21 US Manufacturing
Open in API
Filings indexed 655 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country US United States of America
Listing US EKSO

About EKSO BIONICS HOLDINGS, INC.

https://eksobionics.com/

Ekso Bionics Holdings, Inc. is a developer of robotic exoskeleton technology designed to augment human strength, endurance, and mobility. The company's primary focus is on the medical market, providing solutions for rehabilitation and personal use. Its products assist individuals with lower-extremity paralysis or weakness resulting from conditions such as spinal cord injury (SCI), stroke, acquired brain injury, and multiple sclerosis. Key offerings include the EksoNR, an FDA-cleared exoskeleton for clinical rehabilitation; Ekso Indego Therapy for outpatient settings; and the Ekso Indego Personal, a lightweight system that enables individuals with SCI to stand and walk in home and community environments. The company also develops technology for industrial applications.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 99% confidence The document is a Current Report on Form 8-K filed under the Securities Exchange Act (item 2.05 concerning costs associated with exit or disposal activities). It is not an earnings release, proxy, annual/quarterly report, or presentation, nor does it fit specialized categories like M&A or share repurchase. Therefore, it falls under the general "Regulatory Filings" fallback category (RNS).
2026-06-04 English
8-K/A
Remuneration Information Classification · 85% confidence The document is an amended Current Report on SEC Form 8-K/A under Item 5.02, describing amendments and details of phantom performance-based stock unit awards granted to executive officers and the settlement terms of those awards. This is a detailed executive compensation disclosure. Although filed on Form 8-K, the content is remuneration information regarding top executives. Therefore it best fits the “Remuneration Information (DEF 14A)” category.
2026-05-20 English
10-K/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
Annual Report FY 2025
2026-04-10 English
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
Director's Dealing
2026-03-21 English
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
Director's Dealing
2026-03-21 English
PREM14C - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'Schedule 14C Information Statement' and is an Information Statement pursuant to Section 14(c) of the Securities Exchange Act of 1934. It details stockholder actions by written consent in lieu of a meeting, including approval of a business combination, amendments to articles of incorporation, equity financing, and equity incentive plans. It explicitly states it is not soliciting proxies and that the stockholder approved actions have been adopted by written consent. The document includes detailed disclosures about the transaction, voting, and governance changes. This type of document is a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to inform and request votes or consents for corporate actions, but in this case by written consent rather than a meeting. It is not an Annual Report, Earnings Release, or other financial report. It is not a simple announcement or regulatory filing. The length and detail confirm it is the full Information Statement, not just a notice or announcement. Therefore, the correct classification is PSI with high confidence.
2026-03-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.